Physician profile
Grace Tomko
NPI 1861099277
$4,325.82
in general payments reported to CMS, 2019-2025
25 companies · $1,714 in 2025
The $1,714 reported for 2025 was more than what 91% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $112 · 2022: $144 · 2023: $529 · 2024: $1,826 · 2025: $1,714.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,590 · Education: $480.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,589.72 |
| Education | $479.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $620.12 | 2024-2025 | |
| Sun Pharmaceutical Industries INC. | $602.70 | 2023-2025 | Odomzo, Blu-U, Winlevi |
| Janssen Biotech, INC. | $589.48 | 2023-2025 | Tremfya, Simponi, Stelara |
| Lilly USA, LLC | $467.06 | 2023-2025 | Taltz, Olumiant, Ebglyss |
| Regeneron Healthcare Solutions, INC. | $452.49 | 2021-2025 | Dupixent |
| Amgen INC. | $217.88 | 2021-2025 | Otezla, Otezla |
| Incyte Corporation | $212.43 | 2023-2025 | Opzelura, Opzelura |
| Pfizer INC. | $158.30 | 2023-2025 | |
| Mayne Pharma Commercial LLC | $142.24 | 2023-2025 | |
| Arcutis Biotherapeutics, INC. | $132.40 | 2023-2025 | Zoryve |
| Genzyme Corporation | $112.76 | 2024 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $94.42 | 2023-2025 | Jublia, Cabtreo, Arazlo |
| Leo Pharma INC. | $90.91 | 2025 | Adbry, Anzupgo |
| Amarin Pharma, INC. | $86.98 | 2022 | |
| Esperion Therapeutics, INC. | $74.03 | 2021-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $64.32 | 2023-2025 | Nemluvio, Epsolay, Twyneo |
| Botanix Sb INC | $53.49 | 2025 | Sofdra |
| Ucb, INC. | $48.09 | 2024-2025 | Bimzelx |
| Lnhc, INC | $18.47 | 2025 | Zelsuvmi |
| Journey Medical Corporation | $17.73 | 2024 | |
| Dermavant Sciences, INC. | $17.23 | 2023 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $15.51 | 2024 | Sotyktu |
| Verrica Pharmaceuticals INC. | $14.73 | 2024 | Ycanth |
| Helsinn Therapeutics (U.S.), INC. | $14.52 | 2024 | Valchlor |
| Organon LLC | $7.53 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Grace Tomko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.